Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Study of Daclatasvir and TMC435 for subjects with genotype 1 chronic hepatitis C
To assess efficacy of daclatasvir and TMC435 with and without ribavirin, as determined by the proportion of subjects with SVR12, defined as HCV RNA < LOQ at post-treatment Week 12.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole versus other Atypical Antipsychotics in the Treatment of Schizophrenic Patients with Metabolic Syndrome Revised Protocol 03 Incorporating Protocol Amendment 01 (v1.0, dated 22-Aug-2007), Administrative Letter 01, Protocol Amendment 02 (v1.0, dated 25-Jan-2008), Administrative Letter 02 and Protocol Amendment 03 (v2.0, dated 22-Jul-2008)
The primary objective of this study is to demonstrate superiority of aripiprazole treatment versus current atypical antipsychotic treatment in mean % change in fasting non-HDL cholesterol levels from ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
Efficacy of Aripiprazole in Combination with Valproate or Lithium in the Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy (Revised protocol 1, and amendment 1)
To compare the efficacy of aripiprazole with placebo in combination with lithium or valproate to lithium or valproate monotherapy, as measured by the Y-MRS, in the treatment of Bipolar I Disorder pa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in Combination with Tenofovir/Emtricitabine QD in Treatment Naive HIV-Infected Subjects
The primary objective of this study is to determine the proportion of subjects with HIV RNA < 50 c/mL at Week 24 in HIV-1 infected Treatment-Naive Subjects.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer / Estudio fase II aleatorizado de ixabepilona mas carboplatino y paclitaxel mas carboplatino en sujetos con cancer de pulmon no microcitico avanzado + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 19-Mar-08) / Enmienda sobre muestras de sangre para farmacogenética - Número 01 - Específica de centro
To compare the progression-free survival (PFS) in the ixabepilone plus carboplatin arm to that in the paclitaxel plus carboplatin arm for the subgroup of subjects with ?III tubulin positive tumors (?I...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in Subjects with Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control. “Ensayo de fase 2, multicéntrico, en doble ciego, controlado con placebo, de grupos paralelos y aleatorizado, para evaluar la eficacia hipoglucemiante, la seguridad renal, la farmacocinética y la farmacodinámica de dapagliflozin en sujetos con diabetes mellitus tipo 2 e insuficiencia renal moderada con un inadecuado control glucémico" Revised Protocol 01, incorporating Protocol Amendment 02 (Version 1.0, Date 10-Apr-2008). And Pharmacogenetics Blood Sample Amendment 01 - Site specific (Version 2.0, Date 10-Mar-2008)
To compare the change from baseline in A1C achieved with each dapagliflozin treatment group versus placebo, after 24 weeks of oral administration of double-blind treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Study of an investigational treatment regimen of daclatasvir (DCV) + asunaprevir (ASV) + BMS-791325 in a fixed dose combination (the triple regimen) with or without ribavirin (RBV) for 12 weeks for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in subjects with compensated cirrhosis
To demonstrate the effectiveness of Triple fixed dose combination with or without ribavirin in treatment naive cirrhotic subjects
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who are Intolerant of Imatinib Revised Protocol 01 version 4.0, incorporating Amendment 02 and Administrative Letter dated 01-Mar-2005, and Amendment 01 version 2.0 dated 28-Apr-2005
The primary objective of this study is to estimate the major cytogenetic response (MCyR) rate to BMS-354825 in subjects with Philadelphia chromosome positive chronic phase Ph+ CML who have disease tha...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or Locally Advanced Solid Malignancies. Revised Protocol Number 07, incorporating Amendments 01, 02, 03, 04, 05, 06, 07 and Administrative Letter Dated 10-Mar-2006
To assess the safety and tolerability of BMS-663513 in the range of 0.3 mg/kg to 15 mg/kg administered once every 3 weeks to patients with metastatic or locally advanced solid malignancies in the dose...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/neu-Positive Breast Cancer Revised Protocol 02 incorporating amendments 03 and 04 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0 dated 16-Aug-06) + Pharmacogenomics Tissue Sample Amendment Number 02 - Site Specific - (version 1.0 dated 16-Aug-06)
To estimate, by subgroup, objective response rate (ORR) of dasatinib in women with recurrent or progressive locally-advanced or metastatic breast cancer.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant